Joseph K. Belanoff, M.D., co-founder and CEO of Corcept Therapeutics since 1999, combines a strong medical background with deep experience in the pharma industry. He has an impressive educational background; he earned his B.A. from Amherst College and his M.D....

Joseph K. Belanoff, M.D., co-founder and CEO of Corcept Therapeutics since 1999, combines a strong medical background with deep experience in the pharma industry. He has an impressive educational background; he earned his B.A. from Amherst College and his M.D. from Columbia University’s prestigious College of Physicians & Surgeons. Notably, Dr. Belanoff has been a clinical faculty member at Stanford University for decades, where he has contributed to the field of psychiatry. His leadership at Corcept has been pivotal during significant milestones, including the approval of their drug, Korlym™, for treating Cushing's syndrome, which has made a real impact on patients' lives. In 2023, his total compensation was $2,652,500, reflecting his role in driving the company's performance and aligning with healthcare goals. As a CEO, he emphasizes attracting talented personnel to ensure the company meets its clinical and commercial objectives. His keen focus on scientific and regulatory achievements showcases his strategic approach to building Corcept into a leading therapeutic company.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

C

Joseph K. Belanoff, M.D.

Founder and CEO of Corcept Therapeutics

Education

B.A. from Amherst College and M.D. from Columbia University’s College of Physicians & Surgeons.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1957 - 68 years ago

CEO of Corcept Therapeutics for

26 years 3 months (Jan 1999 - Present)

Previous Experience

Co-founder of the Company and has served as a member of the Board and as the Company’s Chief Executive Officer since 1999. Currently a clinical faculty member at Stanford University.

Rivals

Competitors/colleagues of Joseph K. Belanoff, M.D.

Holdings

See how much did Joseph K. Belanoff, M.D. make over time.

Dr. Belanoff’s financial interests in Corcept Therapeutics reflect a significant investment in the company’s future. In recent years, he received a grant of 500,000 stock options in 2023, but none of those options vested, focusing more on performance-linked compensation. His...

Dr. Belanoff’s financial interests in Corcept Therapeutics reflect a significant investment in the company’s future. In recent years, he received a grant of 500,000 stock options in 2023, but none of those options vested, focusing more on performance-linked compensation. His peak income came in 2021, when he earned over $100 million, largely due to the vesting of stock options tied to company performance. His compensation has shown fluctuations, with varying total earnings from $597,670 in 2015 to over $100 million in 2021, emphasizing the growth and success of Corcept under his guidance. His wealth is intricately linked with the company's success in developing and commercializing effective treatments, indicating a strong alignment of interests between him and shareholders.

Loading...

Total Stock Sold

$25.11M

CORT

$25.11M

1,772,173 CORT shares

What if they kept their stock?

If Joseph K. Belanoff, M.D. didn't sell their stock, today they would have:
Extra CORT1,772,173 shares worth $20.66M.
This is -17.7% and $4.45M less than what they got when they sold the stock.

Charitable Transactions

CORT

539,228 shares

CORT

Recent Charitable Transactions

CORT

539,228 shares

CORT

Dec 31, 2024

Charity

Insider Trading

See recent insider trades of Joseph K. Belanoff, M.D..

CORT

$178.10K

CORT at $60.91/share

Feb 28, 2025

Sale

CORT

539,228 shares

CORT

Dec 31, 2024

Charity

CORT

$8.80M

CORT at $26.26/share

Jul 6, 2022

Sale

CORT

$4.13M

CORT at $19.01/share

Dec 12, 2018

Sale

CORT

$4.13M

CORT at $19.01/share

Dec 12, 2018

Sale

CORT

$4.50M

CORT at $9.00/share

Nov 10, 2016

Sale

CORT

$4.14M

CORT at $8.27/share

Nov 7, 2016

Sale

Compensation History

See how much did Joseph K. Belanoff, M.D. make over time.

In 2023, Dr. Belanoff's total compensation reached $2,652,500, a significant jump from previous years. His salary of $1,100,000 and substantial bonuses of $1,320,000 highlight his performance-driven pay structure. However, no stock options vested in 2023, as the focus remained on long-term growth through newly granted stock options that will vest over four years. His overall compensation has seen dramatic increases over the years, peaking at over $100 million in 2021 when stock options vested, reflecting the company's strong performance in the biopharmaceutical market. The compensation aligns with achieving significant corporate goals, which centers around Corcept’s advancements in drug development and clinical outcomes.

Year

2023

Total Compensation

$2.44M

Salary

$1.10M

Board Justification

The compensation program aims to attract, motivate, and retain highly-qualified executive officers by offering competitive pay linked to performance and company goals.

Bonus

$1.32M

Board Justification

In March 2024, bonuses were paid to all employees, including named executive officers, based on the achievement of significant corporate goals in 2023.

Other

$22.50K

Board Justification

Other compensation includes contributions to the 401(k) Plan and other benefits.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as only stock grants were mentioned, which are excluded from total calculations.

Performance Metrics

Performance metrics include revenue growth, successful completion of clinical trials, and advancements in clinical development programs.